AstraZeneca to invest £120m at Macclesfield plant

astrazenecaosborneThe drugs firm AstraZeneca today made good its pledge to commit its future to its Macclesfield plant with the announcement that it plans to invest £120 million in a new facility at its global manufacturing site there.

The investment means that the global pharmaceutical giant wikll continue production of Zoladex, an injectable treatment for patients with prostate cancer. The company said the investment would secures 300 existing Zoladex jobs at the site and create 200 temporary jobs during the construction and commissioning phase between now and early 2017.

Earlier this year, AstraZeneca promised a future for Macclesfiled when slashing 550 jobs at its plant jobs a few miles away at Alderley Park where it is closing its research and development centre in favour of a re-location, over a three-year period, to a new £330m research base being built in Cambridge.

Zoladex has been manufactured at  Macclesfield for over 25 years and, the company said “continues to be an important asset in AstraZeneca’s oncology portfolio and is currently the company’s fifth largest selling brand with annual sales in the region of $1 billion”.

The company’s David Smith, vice-president of operations, said: “This new facility will support the continued production of this important medicine in the UK. Having considered a number of options globally, we believe it is the right choice to build the new facility in Macclesfield, which has been home to Zoladex manufacturing – and the expertise that goes along with it – for many years. This investment is a further signal of our long term commitment to the UK, and to the North West.”

Commenting on the new investment, Chancellor George Osborne (pictured, right) said: “This is great news for our local community which will save and create hundreds of manufacturing jobs. ”

Copyright Ken Hurst 2013

Advertisements

About Ken Hurst

Ken Hurst began his career as a journalist in London over 30 years ago, working on a range of publications before moving on to weekly newspaper production in the newly-independent Zambia of the 1970s. He returned to the UK where his work included spells on newspapers and magazines, before moving to head up Norwich Union’s corporate affairs division. In the 1990s he moved on to freelance, co-own and publish the B2B audio magazine Sound and front the BBC radio Yesterday’s Papers programme. There followed six years as Business Editor at Britain’s biggest selling regional daily newspaper, The Eastern Daily Press, where he led an award-winning team and for whom he still writes a weekly socio/political comment column. Subsequently, he was Group Editorial Director at CBM, responsible for its UK and US magazine output – including The Manufacturer magazine – research-driven industry reports and live events content. Currently he is Contributing Editor at Works Management magazine publisher Findlay Media and Chairman of the consumer publishing house TNT Multimedia Ltd. He is a Fellow of the Royal Society of Arts and of the British Association of Communicators in Business.
This entry was posted in jobs, Manufacturing management, Moves/expansion, Pharma and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s